Skip to main content Skip to search Skip to main navigation

MHRA: Alignment With EU on Extention of GMP and GDP Certificates

On 11 December, the UK Medicines and Healthcare Products Regulatory Agency (MHRA) announced a validity extension of GMP and GDP certificates.

With the announcement of the return of international on-site inspections in November 2022, the authority announced an extension of the validity of GMP and GDP certificates until the end of 2023. As many of the inspections postponed during the COVID-19 pandemic have yet to be carried out, the MHRA has aligned with the EU regulations on the extension of validity. Their blog post states "The MHRA has decided (in consultation with our international partners) to continue the extension of the validity date until 2024 or until the completion of the next inspection, whichever comes first, unless otherwise stated on the certificate."

Inspections will continue to be prioritised based on risk so that manufacturers and wholesalers with the highest priority will be inspected first. In addition, inspections will be prioritised if the GMP or GDP certificate is already five years or older.


Source:

MHRA: GMP & GDP Certificates: Validity Period Extended

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

EMA: Q&A Paper on Measures to Prevent Microbial Contamination of Non-Sterile Medicinal Products

EMA: Q&A Paper on Measures to Prevent Microbial Contamination of Non-Sterile Medicinal Products

The EMA has published a new Q&A paper on technical and organisational measures to prevent microbial contamination of non-sterile medicinal products.
Read more
Why is import authorisation necessary for medicinal products entering the EU?

Why is import authorisation necessary for medicinal products entering the EU?

Read more
When APS Fail and First Air is at Risk

When APS Fail and First Air is at Risk

At the PDA Good Aseptic Manufacturing Conference 2026, Alberto Gonzales (Takeda) discussed challenges and practical solutions related to aseptic process simulations (APS). Anna Campanella (Takeda) and Hussein Bachir (Franz Ziel) explored how first air protection in aseptic processing can be compromised by equipment design, glove interventions, and operator activities.
Read more
FDA: Updated Compliance Program for Preapproval Inspections

FDA: Updated Compliance Program for Preapproval Inspections

The FDA has revised its Compliance Program 7346.832, “Preapproval Inspections”. The updated program describes the planning, conduct and evaluation of preapproval inspections (PAIs) for New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs).
Read more
EMA: Revised Q&A MRA EU-USA

EMA: Revised Q&A MRA EU-USA

The EMA has updated its Questions and Answers on the EU-US Mutual Recognition Agreement (MRA). The update follows the completion of the FDA's assessment of all EU authorities responsible for GMP inspections of veterinary medicinal products on 29 May 2026.
Read more
WHO: Draft on Regulatory Ovesight of Disposal of Medical Products

WHO: Draft on Regulatory Ovesight of Disposal of Medical Products

WHO published a draft consultation document on regulatory oversight of disposal of medical products throughout the lifecycle.
Read more
Previous
Next